Completed PHASE4 INTERVENTIONAL 2-arm NCT02681978

Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease (RIVENDEL)

Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease: the RIVENDEL Study

Sponsor: Campus Bio-Medico University

Conditions Coronary Artery Disease

Interventions Ivabradine Standard medical therapy

Updated 5 times since 2017 Last updated: Feb 10, 2016 Started: Feb 28, 2014 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02681978, this PHASE4 trial focuses on Coronary Artery Disease and remains completed. Sponsored by Campus Bio-Medico University, it has been updated 5 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Campus Bio-Medico University

Data source: Campus Bio-Medico University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy